Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG: Remibrutinib oral treatment
DRUG: Ocrelizumab

Sponsor

Novartis Pharmaceuticals